Dear Editor,
Melanoma is highly resistant to chemotherapy, other systemic therapies and radiotherapy. Explants and derived cell lines have proved resistant to a variety of proapoptotic stimuli in vitro, leading to suggestions that the resistance to nonsurgical treatments reflects defects in apoptosis pathways, or their downregulation, in melanoma cells.1 Unlike many other tumours, melanomas rarely exhibit defects in p53 function and they also express little BCL2; thus, if there are common blocks in apoptosis pathways in melanoma cells, they must lie elsewhere.
In 2001, Soengas et al2 reported that the gene locus of the caspase-9 coactivator Apaf-1 is subject to loss-of-heterozygosity in approximately 40% of primary melanomas. In addition, fully half of a panel of cell lines derived from metastatic melanomas had abrogated expression of Apaf-1 and this correlated with resistance to the cytotoxic drug doxorubicin. Apaf-1 has been considered central to the activation of caspases through the BCL2-regulated (also called ‘mitochondrial’ or ‘intrinsic’) apoptosis pathway; consequently, these results offered an explanation for chemoresistance in a large fraction of metastatic melanomas. More broadly, it was evident that this mechanism of multidrug resistance is pertinent to recalcitrant solid tumours, which had been questioned.3 Since then, immunohistochemical studies suggested that downregulation of Apaf-1 was associated with melanoma progression and metastasis4 and allelic imbalance at the Apaf-1 locus was associated with adverse treatment outcome.5
However, recent work in one of our groups (by CS and AS) indicated that the absence of Apaf-1 or the associated caspase-9 did not affect either apoptosis or drug sensitivity in a lymphoid tumour model6 or in primary lymphocytes,7 raising doubts that Apaf-1 is crucial to apoptosis. Indeed, a recent study concluded that Apaf-1 is dispensable for normal apoptosis of human melanoma cells.8 We therefore re-examined Apaf-1 expression in 15 melanoma cell lines by SDS-PAGE and immunoblot analyses. Five of the lines originated from primary melanomas and the other 10 from metastatic tumours. Some were obtained from public sources and the others derived from patient biopsies (by PH or GB). Apaf-1 was readily detected in all but one of the 15 lines examined (SK-Mel-110), with either of two monoclonal antibodies (Figure 1). Variation in Apaf-1 levels between the other 14 cell lines was modest given their diverse origins and, with the exception of the one negative line, there was no systematic difference between lines derived from primary or metastatic melanomas. In addition, of the 20 frozen metastatic melanoma sections examined by immunohistochemistry, 17 were clearly positive for Apaf-1; 13 of these showed strong staining and the rest weak to intermediate staining. Thus, although we do find inactivation of Apaf-1 in metastatic melanoma, it appears to occur far less frequently than that previously reported. Our conclusions appear to be supported by a recent analysis of the NCI Cell line Panel, all of which, including the eight melanoma lines therein, express Apaf-1.9 Collectively, these results do not support the view that inactivation of Apaf-1 occurs frequently in the progression from primary to metastatic melanoma, or that such changes could account for the resistance of many melanomas to nonsurgical treatments. We believe that Apaf-1 LOH data should be treated with caution until a role for nearby genes, such as the proapoptotic IKIP,10 is ruled out.
The observation by Soengas et al2 of a relationship between Apaf-1 levels and chemosensitivity in their melanoma lines remains of great interest as evidence that disruption of apoptosis pathways is pertinent to melanoma drug resistance, at least in vitro. Crucially, it remains to be seen whether the same is true of melanomas in vivo, given that cytotoxic drugs, doxorubicin included, are rarely effective in that context. We are also left with the question of what other genetic or epigenetic changes might contribute to the refractory character of melanomas. Recent attention has focused on overexpression of certain caspase-inhibitory IAPs11 and on other members of the Bcl-2 family of pro- and anti-apoptotic proteins.12 We therefore await with interest the results of further studies relating the expression of such genes, including Apaf-1, to treatment responses and survival of patients with primary or metastatic melanoma.
References
Serrone L and Hersey P (1999) Melanoma Res. 9: 51–58
Soengas MS et al. (2001) Nature 409: 207–211
Brown JM and Wouters BG (1999) Cancer Res. 59: 1391–1399
Baldi A et al. (2004) Exp. Dematol. 13: 93–97
Fujimoto A et al. (2004) Cancer Res. 64: 2245–2250
Scott CL et al. (2004) J. Cell. Biol. 164: 89–96
Marsden VS et al. (2002) Nature 419: 634–637
Zanon M et al. (2004) Cancer Res. 64: 7386–7394
Svingen PA et al. (2004) Clin. Cancer Res. 10: 6807–6820
Hofer-Warbinek R et al. (2004) Cell Death Differ. 11: 1317–1325
Kaufman SH and Vaux DL (2003) Oncogene 22: 7414–7430
Huang DC and Strasser A (2000) Cell 103: 839–842
Hausmann G et al. (2000) J. Cell. Biol. 149: 623–634
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on Cell Death and Differentiation website (http://www.nature.com/cdd)
Supplementary information
Rights and permissions
About this article
Cite this article
Allen, J., Zhang, X., Scott, C. et al. Is Apaf-1 expression frequently abrogated in melanoma?. Cell Death Differ 12, 680–681 (2005). https://doi.org/10.1038/sj.cdd.4401634
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cdd.4401634
This article is cited by
-
Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis
Oncogene (2008)
-
BH3-only proteins in cell death initiation, malignant disease and anticancer therapy
Cell Death & Differentiation (2006)